Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation
- 1 December 2002
- journal article
- case report
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 21 (12) , 1304-1309
- https://doi.org/10.1016/s1053-2498(02)00439-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantationThe Journal of Heart and Lung Transplantation, 2001
- Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)Clinical Immunology, 2001
- Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving RituximabNew England Journal of Medicine, 2001
- CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with RituximabAmerican Journal of Hematology, 2000
- Posttransplantation Lymphoproliferative Disorder in Children: Clinical, Histopathologic, and Imaging FeaturesRadiology, 2000
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH THE ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB ALONE IN AN ADULT AFTER LIVER TRANSPLANTATIONTransplantation, 2000
- Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using RituximabLeukemia & Lymphoma, 2000
- Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantationThe Lancet, 1999
- Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disordersThe Lancet, 1998
- The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevantCancer, 1998